Loading...
XASX
FPH
Market cap14bUSD
Sep 18, Last price  
35.21AUD
1D
-0.03%
1Q
12.75%
Jan 2017
334.07%
IPO
1,362.96%
Name

Fisher & Paykel Healthcare Corporation Ltd

Chart & performance

D1W1MN
XASX:FPH chart
P/E
54.36
P/S
10.89
EPS
0.80
Div yield, %
1.72%
Shrs. gr., 5y
0.41%
Rev. gr., 5y
3.63%
Revenues
2.36b
+84.02%
349,242,000345,966,000485,516,000474,755,000467,680,000466,726,000507,250,000568,602,000644,013,000738,745,431796,785,293907,090,1961,029,311,9291,233,448,8931,971,200,0001,681,700,0001,588,600,0001,742,800,0001,280,300,0002,356,030,353
Net income
472m
+25.11%
57,605,00035,276,00062,233,00071,631,00052,466,00064,110,00077,053,00097,053,000113,173,000143,425,000169,152,000190,200,000209,200,000287,300,000524,200,000376,900,000250,300,000132,600,000377,200,000471,911,167
CFO
668m
+21.77%
56,346,00038,375,87651,318,835106,508,33052,244,85273,981,87569,349,32697,644,686144,023,540130,487,997177,379,035233,050,234243,190,664311,316,533625,300,000324,300,000238,200,000429,600,000548,600,000668,028,785
Dividend
Jun 22, 20260.31682 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fisher & Paykel Healthcare Corporation Limited, operating with its various subsidiaries, is a global innovator in medical device technology. The company specializes in the design, production, and worldwide distribution of sophisticated products and systems. These solutions primarily cater to acute and chronic respiratory care, support during surgical procedures, and the treatment of obstructive sleep apnea (OSA) in both clinical settings and home environments. Their product lineup includes notable items such as the Airvo 2, a humidified nasal high flow system; Optiflow, designed for nasal high flow therapy; and the F&P 850 System, which offers both non-invasive and invasive ventilation capabilities. For infant care, the company supplies respiratory products used in resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Hospital-grade offerings comprise humidification devices, breathing circuits, chambers, diverse masks, nasal cannulas, surgical accessories, and various interfaces. For homecare users, Fisher & Paykel provides masks, CPAP devices, data management software, humidifiers, and complementary accessories. Established in 1934, the company maintains its headquarters in Auckland, New Zealand.

Key people

Lyndal Jane York
Chief Financial Officer · since 2019
Paul Nigel Shearer
Senior Vice President - Sales and Marketing · since 2001
Marcus Driller
Vice President - Corporate · since 2019
Winston Fong
Vice President - Surgical Technologies · since 2017
Nicholas Fourie
Vice President � Information & Communication Technology · since 2017
Debra Lumsden
Vice President of Human Resources and Private Officer · since 2016
Brian Schultz
Vice President - Quality & Regulatory · since 2015
Andrew Robert Donald Somervell
Vice President - Products & Technology · since 2016
Lewis George Gradon
Chief Executive Officer, Managing Director, Director · since 2016
Jonti Rhodes
General Manager - Supply Chain · since 2015
Non-Executive Director · since 2016
Non-Executive Independent Director · since 2017
Non-Executive Independent Director · since 2014
Arthur James Morris
Non-Executive Independent Director · since 2008
Non-Executive Independent Director · since 2014
Non-Executive Independent Director · since 2015
IPO date
Nov 13, 2001
Employees
6,391
Domiciled in
NZ
Incorporated in
NZ

Valuation

Title
NZD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT